Panagiotis Mastorakos1,2, Zhiyuan Xu1, James Yu3, Judith Hess4, Jack Qian3, Ajay Chatrath1, Davis G Taylor1, Douglas Kondziolka5, Ronald Warnick6, Veronica Chiang4, Jason Sheehan1,7. 1. Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia. 2. Department of Neurological Surgery, National Institutes of Health, Bethesda, Maryland. 3. Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut. 4. Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut. 5. Department of Neurosurgery, New York University, New York, New York. 6. Department of Neurosurgery, University of Cincinnati, Cincinnati, Ohio. 7. Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia.
Abstract
BACKGROUND: The BRAF mutation has been identified as a potent target for the treatment of metastatic melanoma and BRAF inhibitors (BRAFi) have demonstrated promising results against melanoma brain metastases (BM). OBJECTIVE: To further investigate the effectiveness of this combined treatment regimen. METHODS: In this multicenter retrospective cohort study, 198 patients with known BRAF mutation status and treated with stereotactic radiosurgery (SRS) between 2011 and 2015 were identified. Kaplan-Meier methodology and multivariate regression analysis was then used to compare survival based on each parameter. RESULTS: The median survival after the diagnosis of BM in patients with BRAF mutation who received BRAFi was increased compared to survival in patients with wild-type BRAF (BRAF wt). In multivariate analysis, the BRAF mutation was an independent, positive prognostic factor with a hazard ratio of 0.59. BRAF mutated Patients who received BRAFi following SRS had improved survival compared to patients who received it before (P < .001) or concurrently (P = .007). PD-1 inhibitors improved survival, with more pronounced effect in patients not carrying the BRAF mutation. Among the patients who were treated with BRAFi, 10.4% developed intracerebral hematoma (ICH), in comparison to 3% of patients who were not treated with BRAFi (P = .03). CONCLUSION: In the setting of widespread use of BRAFi, the presence of a BRAF mutation is an independent predictor of better prognosis in patients with melanoma BM that underwent SRS. The effect of BRAFi is optimal when treatment is initiated at least 1 wk following SRS. BRAFi may increase the frequency of asymptomatic ICH. Published by Oxford University Press on behalf of Congress of Neurological Surgeons 2018.
BACKGROUND: The BRAF mutation has been identified as a potent target for the treatment of metastatic melanoma and BRAF inhibitors (BRAFi) have demonstrated promising results against melanoma brain metastases (BM). OBJECTIVE: To further investigate the effectiveness of this combined treatment regimen. METHODS: In this multicenter retrospective cohort study, 198 patients with known BRAF mutation status and treated with stereotactic radiosurgery (SRS) between 2011 and 2015 were identified. Kaplan-Meier methodology and multivariate regression analysis was then used to compare survival based on each parameter. RESULTS: The median survival after the diagnosis of BM in patients with BRAF mutation who received BRAFi was increased compared to survival in patients with wild-type BRAF (BRAF wt). In multivariate analysis, the BRAF mutation was an independent, positive prognostic factor with a hazard ratio of 0.59. BRAF mutated Patients who received BRAFi following SRS had improved survival compared to patients who received it before (P < .001) or concurrently (P = .007). PD-1 inhibitors improved survival, with more pronounced effect in patients not carrying the BRAF mutation. Among the patients who were treated with BRAFi, 10.4% developed intracerebral hematoma (ICH), in comparison to 3% of patients who were not treated with BRAFi (P = .03). CONCLUSION: In the setting of widespread use of BRAFi, the presence of a BRAF mutation is an independent predictor of better prognosis in patients with melanoma BM that underwent SRS. The effect of BRAFi is optimal when treatment is initiated at least 1 wk following SRS. BRAFi may increase the frequency of asymptomatic ICH. Published by Oxford University Press on behalf of Congress of Neurological Surgeons 2018.
Authors: Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Shaowei Wu; Helen Kuo; Wen-Qing Li; Alvaro Laga Canales; Jiali Han; Abrar A Qureshi Journal: Cancer Causes Control Date: 2014-07-22 Impact factor: 2.506
Authors: Göran Jönsson; Christian Busch; Stian Knappskog; Jürgen Geisler; Hrvoje Miletic; Markus Ringnér; Johan R Lillehaug; Ake Borg; Per Eystein Lønning Journal: Clin Cancer Res Date: 2010-05-11 Impact factor: 12.531
Authors: James J Harding; Federica Catalanotti; Rodrigo R Munhoz; Donavan T Cheng; Amin Yaqubie; Nicole Kelly; Gregory C McDermott; Romona Kersellius; Taha Merghoub; Mario E Lacouture; Richard D Carvajal; Katherine S Panageas; Michael F Berger; Neal Rosen; David B Solit; Paul B Chapman Journal: Oncologist Date: 2015-05-08
Authors: Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas Journal: N Engl J Med Date: 2012-02-23 Impact factor: 91.245
Authors: M Hecht; L Zimmer; C Loquai; C Weishaupt; R Gutzmer; B Schuster; S Gleisner; B Schulze; S M Goldinger; C Berking; A Forschner; P Clemens; G Grabenbauer; T Müller-Brenne; J Bauch; H T Eich; S Grabbe; D Schadendorf; G Schuler; P Keikavoussi; S Semrau; R Fietkau; L V Distel; L Heinzerling Journal: Ann Oncol Date: 2015-03-11 Impact factor: 32.976
Authors: Pierre-Yves Borius; Jean Régis; Alexandre Carpentier; Michel Kalamarides; Charles Ambroise Valery; Igor Latorzeff Journal: Cancer Metastasis Rev Date: 2021-01-04 Impact factor: 9.264
Authors: Norbert Galldiks; Martin Kocher; Garry Ceccon; Jan-Michael Werner; Anna Brunn; Martina Deckert; Whitney B Pope; Riccardo Soffietti; Emilie Le Rhun; Michael Weller; Jörg C Tonn; Gereon R Fink; Karl-Josef Langen Journal: Neuro Oncol Date: 2020-01-11 Impact factor: 12.300
Authors: Mark P van Opijnen; Linda Dirven; Ida E M Coremans; Martin J B Taphoorn; Ellen H W Kapiteijn Journal: Int J Cancer Date: 2019-11-23 Impact factor: 7.396